Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-244X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study ; volume:20 ; number:1 ; day:5 ; month:5 ; year:2020 ; pages:1-13 ; date:12.2020
BMC psychiatry ; 20, Heft 1 (5.5.2020), 1-13, 12.2020
- Creator
-
Mattingly, Greg W.
Haddad, Peter M.
Tocco, Michael
Xu, Jane
Phillips, Debra
Pikalov, Andrei
Loebel, Antony
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12888-020-02523-1
- URN
-
urn:nbn:de:101:1-2020071221205644148507
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:57 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Mattingly, Greg W.
- Haddad, Peter M.
- Tocco, Michael
- Xu, Jane
- Phillips, Debra
- Pikalov, Andrei
- Loebel, Antony
- SpringerLink (Online service)
Other Objects (12)
Atenolol in the prophylaxis of chronic migraine: a 3-month open-label study
Vortioxetine in children and adolescents with major depressive disorder: 6-month and 18-month open-label, flexible-dose, long-term extension studies
Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study
Reports / 6-Months / 18-Months
Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial
Efficacy and Safety of Sodium Zirconium Cyclosilicate for Treatment of Hyperkalemia: An 11-Month Open-Label Extension of HARMONIZE
A 6-month, multicenter, open-label study of fixed dose naproxen/esomeprazole in adolescent patients with juvenile idiopathic arthritis
Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension
Months Together - Months Apart: Dokumente einer Fernbeziehung
JEWELFISH: 24-month results from an open-label study in non-treatment-naïve patients with SMA receiving treatment with risdiplam
JEWELFISH: 24-month results from an open-label study in non-treatment-naïve patients with SMA receiving treatment with risdiplam
Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial
Atenolol in the prophylaxis of chronic migraine: a 3-month open-label study
Vortioxetine in children and adolescents with major depressive disorder: 6-month and 18-month open-label, flexible-dose, long-term extension studies
Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study
Reports / 6-Months / 18-Months
Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial
Efficacy and Safety of Sodium Zirconium Cyclosilicate for Treatment of Hyperkalemia: An 11-Month Open-Label Extension of HARMONIZE
A 6-month, multicenter, open-label study of fixed dose naproxen/esomeprazole in adolescent patients with juvenile idiopathic arthritis
Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension
Months Together - Months Apart: Dokumente einer Fernbeziehung
JEWELFISH: 24-month results from an open-label study in non-treatment-naïve patients with SMA receiving treatment with risdiplam
JEWELFISH: 24-month results from an open-label study in non-treatment-naïve patients with SMA receiving treatment with risdiplam
Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial
Atenolol in the prophylaxis of chronic migraine: a 3-month open-label study
Vortioxetine in children and adolescents with major depressive disorder: 6-month and 18-month open-label, flexible-dose, long-term extension studies
Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study
Reports / 6-Months / 18-Months
Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial
Efficacy and Safety of Sodium Zirconium Cyclosilicate for Treatment of Hyperkalemia: An 11-Month Open-Label Extension of HARMONIZE
A 6-month, multicenter, open-label study of fixed dose naproxen/esomeprazole in adolescent patients with juvenile idiopathic arthritis
Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension
Months Together - Months Apart: Dokumente einer Fernbeziehung
JEWELFISH: 24-month results from an open-label study in non-treatment-naïve patients with SMA receiving treatment with risdiplam
JEWELFISH: 24-month results from an open-label study in non-treatment-naïve patients with SMA receiving treatment with risdiplam